The global gene expression market size was estimated at USD 6.81 billion in 2016. Gene expression analysis supports cutting-edge research and enables scientific discoveries by providing insights into gene function at molecular levels. Gain or loss of function results in changes in phenotype, intracellular localization and probable other changes that might have caused the disease. Increased focus on advanced healthcare framework and adoption of advanced technology in modern diagnostics and drug development. These advances are expected to drive revenue generation.
Identification of molecular pathways of drug response and that of pathogenesis have leveraged the drug development and disease modeling sections. Use of gene profiling studies for the development of novel therapeutics have also increased owing to the resultant reduction in turnaround time and cost associated with more efficient results. Rapid diagnostic tests using these systems are available for diseases with symptoms that are either complicated or pose ambiguity with other diseases.
Decline in the cost of genetic sequencing over past decade has enabled its adoption clinical applications. Introduction of the Precision Medicine Initiative has accelerated adoption of advanced technological tools in medicine and similar healthcare initiatives are anticipated to provide lucrative avenues for growth.
Cap Analysis of Gene Expression (CAGE) that allows comprehensive mapping of human transcription start sites and their promoters have been introduced to overcome the limitations of microarrays. It allows quantification of mRNA sets within a cell. The market witnesses frequent upgradation of products with advances in technology and introduction of novel techniques or platforms, a factor that is anticipated to drive further development.
Global rise in cancer incidence with an increase in a number of unique cases has become a point of key interest for all healthcare organizations. Tracing the cause to be a mutation in function, studying manifestation patterns of particular genes that would help design precision medicine treatment for cancer patients and help reduce recurrence/relapse rate is another important driver for revenue generation.
The steps involved in the transcription of genes into functional gene products, proteins, and functional RNAs have various commercial implications and thus attract different revenue shares. At various steps along the process information related to normal cellular processes as well as abnormal or pathological pathways is accumulated. A defect in any step from transcription of DNA code into RNA to synthesis of protein can lead to abnormal manifestation of the nucleic acids.
PCR systems have witnessed frequent upgradations with introduction of RT-PCR and qPCR along with their enhanced versions. PCR analysis is estimated to have the largest revenue share owing to high adoption and introduction of systems integrated with other steps as well as techniques.
Gene manifestation research is useful only with accurate data processing & interpretation. Rise in demand for better analytic tools for genomic studies has encouraged players to invest in development of this software. Players offering customized services for expression data analysis have entered into the market. Large amounts of “omics” data has been generated over the years post introduction of sequencing technology, thereby accelerating the demand for analytic platforms. Thus, data analysis & interpretation process is estimated to witness rapid growth over the forecast period.
Kits & reagents dominate the gene expression market with largest revenue share due to higher usage of these products irrespective of which technique is adopted. Though the prices are comparatively lower, however, the sales volumes are high enough to make these account for a larger share. The launch of novel kits and reagents with enhanced efficiency are projected to drive revenue generation over the forecast period.
Moreover, rising demand for better data interpretation & visualization has encouraged companies to enhance bioinformatics tools and platforms to meet the needs of modern day research. Introduction of platforms that provide simple tools such as topology enrichment and differential co-manifestation research that cater to the specific needs of the end users also constitute a significant section of the product portfolio.
Powerful statistical tools that enable intuitive data analysis and visualization are available. Alignment with NGS data and correlation with other data types with these tools can be used to identify targets of interest. With rise in number of experts with integrated knowledge of computation and biotechnology, advances in data analytics and interpretation platforms is expected over the coming years.
Advances in stem cell research and genetic engineering with scientists trying to manipulate and control gene expression levels in living systems have promoted the development of low- and mid-plex techniques that use sample size with about 1,000 targets as well as high throughput multiplexing techniques. Rise in number of research related to single cell analysis, stem cell therapy, regenerative therapy, and cancer genomics, these techniques are anticipated to fuel market growth.
Development of multiplexed digital characterization systems that have spatially resolved solutions that eliminate the need for upfront probe validation has made high-plex techniques simpler with increased accuracy. Screening whole genome or larger sample sizes for identification of biomarker for potential therapies is attributive to lucrative growth of high-plex capacity techniques.
PCR analysis and DNA microarrays are well-established techniques that exhibit high adopted by researchers and biologists to study expressions of various genes and microorganisms. Integration of these techniques with others such as immunoprecipitation assay (ChIP-PCR and ChIP-chip) to enhance their performance and suit more specific targeting requirements can be attributed to anticipated further usage potential.
Emergence of next generation sequencing has revolutionized the various fields of genetics including expression profiling. RNA sequencing offers high precision analysis for sequence data in a broad range from as small as 25 or 30 ng of total RNA to the entire mammalian genome. RNA expression techniques are poised to have significant growth over the forecast period.
High cost and time associated with drug development and its commercial launch have increased the interest of major pharmaceutical players to invest in alternative options that can increase the efficiency of the whole process. Gene expression analysis of cells before and after treatment with the drug under investigation helps accelerate the drug development process.
Furthermore, the associated ability of expression analysis to provide early and precise diagnosis to predict occurrence of rare genetic condition such as early onset infection (EOI) in preterm infants is another key aspect projected to drive adoption of gene expression in clinical diagnostic tests. Integration of bioinformatics and computation algorithms with enhanced platforms for better diagnosis and tracking disease progression would generate lucrative avenues for adoption in clinical testing settings.
North America dominated the global market in 2016 in terms of revenue share. This is due to the presence of a substantial number of well-established players in the region. Increased focus on advanced healthcare, government support to initiatives that promote precision medicine, high investments in genomic research, further contribute to revenue generation.
However, Asia Pacific is projected to witness fastest growth over the coming years. Changes in government policies of emerging economies that encourage foreign investments along with increased interest from well-established players to capture the untapped market in the region is attributive to developments in this region. In addition, countries such as China and Japan are observed to have considerable number of private investors entering the gene therapy and related fields which, in turn is expected to fuel demand for gene expression.
Major entities operating in this market include QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Novogene Corporation, PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, GE Healthcare Dharmacon Inc., Promega Corporation, Luminex Corporation, TAKARA BIO INC., and Danaher. The market players are involved in the development of novel kits and reagents to enhance the process of expression analysis.
Furthermore, they are engaged in strategic partnerships to expand their market reach. Key players are also involved acquisition of smaller players to enhance product portfolio. For instance, ThermoFisher acquired Affymetrix, Inc. and Life Technologies Corporation. Another acquisition that was witnessed was of Cepheid by Danaher in 2016.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa.
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at regional & country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the gene expression market on the basis of process, product, capacity, technique, application, and regions:
Process Outlook (Revenue, USD Million; 2014 - 2025)
cDNA synthesis & conversion
Data analysis & interpretation
Product Outlook (Revenue, USD Million; 2014 - 2025)
Kits & Reagents
Capacity Outlook (Revenue, USD Million; 2014 - 2025)
Low- to Mid- Plex
Technique Category Outlook (Revenue, USD Million; 2014 - 2025)
In vitro Transcription/Nuclear Run-On Assays
Gel Shift Assays
Chromatin Immunoprecipitation (ChIP)
Protein Expression & Posttranslational Modification Analysis
2-D Gel Electrophoresis
Application Outlook (Revenue, USD Million; 2014 - 2025)
Drug Discovery & Development
Biotechnology & Microbiology
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Middle East and Africa (MEA)
b. The global gene expression market size was estimated at USD 8.1 billion in 2019 and is expected to reach USD 8.5 billion in 2020.
b. The global gene expression market is expected to grow at a compound annual growth rate of 5.9% from 2020 to 2025 to reach USD 11.4 billion by 2025.
b. Kits & reagents dominated the gene expression market with a share of 74% in 2019. This is attributable to high penetration of kits and reagents in the space in terms of product availability, usage rate, and purchase frequency.
b. Some key players operating in the gene expression market include QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, GE Healthcare, and TAKARA BIO INC.
b. Key factors that are driving the market growth include increasing interest of research entities in transcriptomic profiling coupled with technological advancements in genomic technologies in terms of accuracy, specificity, and outcome.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.